Prostate cancer screening: Canadian guidelines 2011

Journal of the Canadian Urological Association

Volumn 5, Issue 4, 2011, Pages 235-240

  Izawa, Jonathan I ^a   Klotz, Laurence ^b   Robert Siemens, D ^c   Kassouf, Wassim ^d   So, Alan ^e   Jordan, John ^a   Chetner, Michael ^f   Iansavichene, Alla E ^a  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961203286     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.11134     Document Type: Article

References (68)

1. Ries LA, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2005. Bethesda: NCI. http:// seer.cancer.gov/csr/1975_2005/. Accessed July 5, 2011.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
3. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
4. Canadian Cancer Society's Steering Committee: Canadian Cancer Statistics 2009. Toronto: Canadian Cancer Society, 2009.
5. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early- stage prostate cancer: a review of literature. Cancer 2008;112:1650-9.
6. Yin M, Bastacky S, Chandran U, et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008;179:892-5; discussion 895. Epub 2008 Jan 22.
7. Yatani R, Chagusi I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982;29:611-6.
8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostatespecific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350:2239-46. Erratum in: N Engl J Med 2004;351:1470.
9. Richie JP, Kavoussi LR, Ho GT, et al. Prostate cancer screening: role of the digital rectal examination and prostate-specific antigen. Ann Surg Oncol 1994;1:117-20.
10. Gosselaar C, Roobol MJ, Roemeling S, et al. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate 2006;66:625-31.
11. Schroder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90:1817-23.
12. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1C) prostate cancer. JAMA 1994;271:368-74.
13. Loeb S, Gonzalez CM, Roehl KA, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006;175:902-6.
14. Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011;185:126-31. Epub 2010 Nov 12.
15. Thompson IM, Ankerst DP, Weiss NS, et al. Operation characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
16. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
17. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003;289:2695-700.
18. Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol 2008;129:952-8.
19. Etzioni RD, Ankerst DP, Weiss NS, et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007; 99: 1510-5.
20. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
21. Carter HB, Person JD, Metter J, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
22. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life- threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-7.
23. Moul JW, Sun L, Hotaling JM, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007;177:499-503; discussion 503-4.
24. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
25. Djavan B, Remzi M, Zlotta AR, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to- total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002;60:(4 Suppl 1):4-9.
26. Augustin H, Graefen M, Palisaar J, et al. Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: Implications for staging. J Clin Oncol 2003;21:2860-8.
27. Resnick MI, Smith JA Jr, Scardino PT, et al. Transrectal prostate ultrasonography: Variability of interpretation. J Urol 1997;158:856-60.
28. Becker C, Lilja H. Individual prostate-specific antigen (PSA) forms as prostate tumor markers. Clin Chim Acta 1997;257:117-32.
29. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-7.
30. Tzanakis I, Kazoulis S, Girousis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron 2002;90:230-3.
31. Mitchell ID, Croal BL, Dickie A, et al. A prospective study to evaluate the role of complexed prostatespecific antigen and free/total prostate- specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001;165:1549-53.
32. Roobol MJ, Schröder FH, van Leeuwen P, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
33. Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-7.
34. Scattoni V, Maccagnano C, Zanni G, et al. Is extended and saturation biopsy necessary? Int J Urol 2010;17:432-47.
35. Remzi M, Fong YK, Dobrovits M, et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005;174:1256-60.
36. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8.
37. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51. Erratum in: JAMA 1997;278:118.
38. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
39. Epstein JI, Walsh PC, Carmichael M, et al. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
40. Jeldres C, Suardi N, Walz J, et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306-13.
41. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171:2122-7.
42. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology 2010;255:89-99.
43. Chun FK, Haese A, Ahyai SA, et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008;113:701-9.
44. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
45. Van As NJ, Parker CC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer 2007;13:289-94.
46. Carter HB, Ketterman A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the John's Hopkins experience. J Urol 2007;178:2359-64.
47. Soloway MS, Soloway CT, Williams S, et al. Active surveillance: a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008;101:165-9.
48. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007;51:1244-50.
49. Van den Bergh RC, Roemeling S, Roobol MJ, et al. Prostate-specific antigen kinetics in clinical decisionmaking during active surveillance for early prostate cancer-a review. BJU Int 2009;54:505-16.
50. Khatami A, Aus G, Damber JE, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-4.
51. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
52. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
53. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-54.
54. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC Trial 22911). Lancet 2005;366:572-8.
55. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces the risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956-62.
56. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
57. Humphrey LL, Helfand M, Chan BK, et al. Breast cancer screening: a summary of the evidence for the US Preventative Services Task Force. Annals Int Med 2002;137:347-60.
58. Nam RK, Zhang WW, Trachtenberg J, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009;15:1787-93.
59. Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
60. Herman MP, Dorsey P, John M, et al. Techniques and predictive models to improve prostate cancer detection. Cancer 2009;115(13 Suppl):3085-99.
61. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 Update. J Urol 2009;182:2232-41.
62. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001;58:411-6.
63. Loeb S, Roehl KA, Antenor JAV, et al. Baseline prostate-specific antigen compared with median prostatespecific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67:316-20.
64. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-6.
65. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. BMC Med 2008;6:6.
66. Ross KS, Guess HA, Carter HB. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology 2005;66:1038-42.
67. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
68. Screening for prostate cancer: U.S. Preventative Services Task Force recommendation statement. Ann Int Med 2008;149:185-91.